Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy

Author： Lötsch Jörn   Hofmann Wolf Peter   Schlecker Christina   Zeuzem Stefan   Geisslinger Gerd   Ultsch Alfred   Doehring Alexandra  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.12, 2011-12, pp. : 1729-1740

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population

By  

Journal of Digestive Diseases, Vol. 16, Iss. 2, 2015-02 ,pp. : 90-97

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is there clinical utility to IL28B genotype testing in the treatment of chronic hepatitis C virus infection?

By Liapakis AnnMarie   Jesudian Arun B  

Pharmacogenomics, Vol. 13, Iss. 12, 2012-09 ,pp. : 1317-1319

Future Medicine

Access to resources Recommend Favorite

Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes

By Lagging Martin  

Pharmacogenomics, Vol. 13, Iss. 8, 2012-06 ,pp. : 847-849

Future Medicine

Access to resources Recommend Favorite

Nucleosides with anti-hepatitis B virus activity

By  

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 3, 2001-03 ,pp. : 503-505

Informa Healthcare

Access to resources Recommend Favorite

Design and Development of Anti-Hepatitis B Virus Agents

By  

Current Medicinal Chemistry, Vol. 17, Iss. 29, 2010-10 ,pp. : 3377-3392

Bentham Science Publishers

Access to resources Recommend Favorite